The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

C.J. Weber; M.C. Carrillo; W. Jagust; C.R. Jack; L.M. Shaw; J.Q. Trojanowski; A.J. Saykin; L.A. Beckett; C. Sur; N.P. Rao; P.C. Mendez; S.E. Black; K. Li; T. Iwatsubo; Chia-Chen Chang; A.L. Sosa; C.C. Rowe; R.J. Perrin; J.C. Morris; A.M.B. Healan; S.E. Hall; M.W. Weiner

doi:10.1002/trc2.12226

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

C.J. Weber, M.C. Carrillo, W. Jagust, C.R. Jack, L.M. Shaw, J.Q. Trojanowski, A.J. Saykin, L.A. Beckett, C. Sur, N.P. Rao, P.C. Mendez, S.E. Black, K. Li, T. Iwatsubo, Chia-Chen Chang, A.L. Sosa, C.C. Rowe, R.J. Perrin, J.C. Morris, A.M.B. HealanS.E. Hall, M.W. Weiner

Department of Medical Biotechnology and Laboratory Science

Research output: Contribution to journal › Journal Article › peer-review

39 Scopus citations

Abstract

The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.

Original language	American English
Journal	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volume	7
Issue number	1
DOIs	https://doi.org/10.1002/trc2.12226
State	Published - 2021

Keywords

Alzheimer's disease
Alzheimer's disease
MRI
MRI
PET
PET
Tau
Tau
amyloid
amyloid
biomarkers
biomarkers
cerebrospinal fluid
cerebrospinal fluid
cognitive impairment
cognitive impairment
neuroimaging
neuroimaging

Access to Document

10.1002/trc2.12226

Cite this

Weber, C. J., Carrillo, M. C., Jagust, W., Jack, C. R., Shaw, L. M., Trojanowski, J. Q., Saykin, A. J., Beckett, L. A., Sur, C., Rao, N. P., Mendez, P. C., Black, S. E., Li, K., Iwatsubo, T., Chang, C.-C., Sosa, A. L., Rowe, C. C., Perrin, R. J., Morris, J. C., ... Weiner, M. W. (2021). The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 7(1). https://doi.org/10.1002/trc2.12226

@article{e37663314b9742d0839c1ba4ab83b1e0,

title = "The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives",

abstract = "The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.",

keywords = "Alzheimer's disease, Alzheimer's disease, MRI, MRI, PET, PET, Tau, Tau, amyloid, amyloid, biomarkers, biomarkers, cerebrospinal fluid, cerebrospinal fluid, cognitive impairment, cognitive impairment, neuroimaging, neuroimaging",

author = "C.J. Weber and M.C. Carrillo and W. Jagust and C.R. Jack and L.M. Shaw and J.Q. Trojanowski and A.J. Saykin and L.A. Beckett and C. Sur and N.P. Rao and P.C. Mendez and S.E. Black and K. Li and T. Iwatsubo and Chia-Chen Chang and A.L. Sosa and C.C. Rowe and R.J. Perrin and J.C. Morris and A.M.B. Healan and S.E. Hall and M.W. Weiner",

year = "2021",

doi = "10.1002/trc2.12226",

language = "American English",

volume = "7",

journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",

issn = "2352-8737",

publisher = "John Wiley and Sons Inc",

number = "1",

}

Weber, CJ, Carrillo, MC, Jagust, W, Jack, CR, Shaw, LM, Trojanowski, JQ, Saykin, AJ, Beckett, LA, Sur, C, Rao, NP, Mendez, PC, Black, SE, Li, K, Iwatsubo, T, Chang, C-C, Sosa, AL, Rowe, CC, Perrin, RJ, Morris, JC, Healan, AMB, Hall, SE & Weiner, MW 2021, 'The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 7, no. 1. https://doi.org/10.1002/trc2.12226

TY - JOUR

T1 - The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

AU - Weber, C.J.

AU - Carrillo, M.C.

AU - Jagust, W.

AU - Jack, C.R.

AU - Shaw, L.M.

AU - Trojanowski, J.Q.

AU - Saykin, A.J.

AU - Beckett, L.A.

AU - Sur, C.

AU - Rao, N.P.

AU - Mendez, P.C.

AU - Black, S.E.

AU - Li, K.

AU - Iwatsubo, T.

AU - Chang, Chia-Chen

AU - Sosa, A.L.

AU - Rowe, C.C.

AU - Perrin, R.J.

AU - Morris, J.C.

AU - Healan, A.M.B.

AU - Hall, S.E.

AU - Weiner, M.W.

PY - 2021

Y1 - 2021

N2 - The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.

AB - The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.

KW - Alzheimer's disease

KW - MRI

KW - PET

KW - Tau

KW - amyloid

KW - biomarkers

KW - cerebrospinal fluid

KW - cognitive impairment

KW - neuroimaging

U2 - 10.1002/trc2.12226

DO - 10.1002/trc2.12226

M3 - Journal Article

C2 - 35005206

SN - 2352-8737

VL - 7

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

IS - 1

ER -

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

Abstract

Keywords

Access to Document

Fingerprint

Cite this